20 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
Guangdong Pharmaceutical University
Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists.
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors.
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH.
Guangdong Pharmaceutical University
Design, synthesis, biological evaluation and in silico studies of novel quinoline derivatives as potential radioprotective molecules targeting the TLR2 and p53 pathways.
Guangdong Pharmaceutical University
Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists.
Guangdong Pharmaceutical University
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
Guangdong Pharmaceutical University
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
Guangdong Pharmaceutical University
Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone.
Guangdong Pharmaceutical University
Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
Guangdong Pharmaceutical University
Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
Guangdong Pharmaceutical University
Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
Guangdong Pharmaceutical University
Design, synthesis and biological activity of deuterium-based FFA1 agonists with improved pharmacokinetic profiles.
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Guangdong Pharmaceutical University
Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents.
Guangdong Pharmaceutical University
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.
Guangdong Pharmaceutical University
Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.
Guangdong Pharmaceutical University